ACTR707 + rituximab

ACTR707 + rituximab is a combination therapy consisting of an autologous, genetically engineered T cell product (ACTR707), which expresses a chimeric receptor (CD16V-CD28-CD3ζ), and the anti-CD20 monoclonal antibody rituximab. The ACTR707 platform is designed so that the T cell is activated only in the presence of rituximab-bound target cells—specifically CD20-positive B cells. This allows the cell-killing capability of T cells to be directed to tumors targeted by the coadministered antibody. The combination was evaluated in a phase I clinical trial for patients with relapsed or refractory CD20-positive B cell non-Hodgkin lymphoma. The trial showed a promising overall response rate and safety profile, with no dose-limiting toxicities or fatal events. ACTR707 is developed by Unum Therapeutics and was discontinued, but the results have implications for future applications of antibody-coupled T cell receptor therapies. Rituximab is a well-established anti-CD20 monoclonal antibody used primarily in B cell malignancies.[1][2][3][5][6][8]